For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 180d
$447.54
Thesis
Vertex runs a near-monopoly in cystic fibrosis with the Trikafta/Kaftrio franchise generating roughly $10B+ in annual revenue, funding one of biotech's most disciplined R&D engines. That cash flow is now backing a diversification beyond CF into gene editing and non-opioid pain, which transforms the story from a single-disease specialist into a multi-franchise platform.
Casgevy, partnered with CRISPR Therapeutics, is the first FDA-approved CRISPR/Cas9 therapy and addresses sickle cell disease and transfusion-dependent beta thalassemia. Journavx (suzetrigine), approved January 2025, is a first-in-class NaV1.8 inhibitor for moderate-to-severe acute pain, opening a non-opioid category the company can own commercially.
Catalysts
- Casgevy patient activations and authorized treatment center ramp
- Journavx adoption in post-surgical settings and label expansion into chronic pain
- Next-gen CF triple combo (vanzacaftor) cannibalization economics
- Pipeline readouts in APOL1-mediated kidney disease and type 1 diabetes cell therapy